Inhibition of Caspase-6 Activation as a Therapeutic Strategy in Neurodegenerative Diseases

Presenter

Jamie Seo

Campus

UMass Amherst

Sponsor

Jeanne Hardy, Department of Chemistry, UMass Amherst

Schedule

Session 4, 2:30 PM - 3:15 PM [Schedule by Time][Poster Grid for Time/Location]

Location

Poster Board A74, Campus Center Auditorium, Row 4 (A61-A80) [Poster Location Map]

Abstract

This study investigates the therapeutic potential of a novel compound synthesized in our laboratory, KT-57, aimed at inhibiting caspase-6 activation in a mouse model. The project is grounded in the premise that caspase-6 plays a crucial role in neurodegenerative processes, particularly in Alzheimer's and Parkinson's diseases. We induced an inflammatory response in preclinical mouse models using lipopolysaccharide (LPS) treatment to activate caspase-6, simulating pathological conditions akin to these neurodegenerative diseases. Studies have shown that caspase-6 activation contributes to cognitive deficits and could be a driving force in the progression of neurodegenerative diseases.

Our approach evaluates the efficacy of our synthesized compound in mitigating caspase-6 activation, with a focus on its potential as a drug target for Alzheimer's and Parkinson's disease treatment. The rationale is anchored in existing research, which links caspase-6 to axonal degeneration and cognitive impairment in Alzheimer's disease, as well as its involvement in the inflammatory response, a key aspect of Parkinson's pathology.

This study not only aims to provide insights into the molecular mechanisms of neurodegeneration but also endeavors to explore new avenues for therapeutic intervention. The results could pave the way for novel treatments that specifically target caspase-6, offering hope in the battle against these debilitating diseases. 

Keywords

Potential drug targets, Neurodegenerative diseases, Mouse models, inhibitors , biochemistry

Research Area

Chemistry and Materials Science

SIMILAR ABSTRACTS (BY KEYWORD)